Skip to main content
  • Clinical
      |Clinical
    • Acute Coronary Syndromes
    • Cardiac Surgery
    • Covid-19
    • Heart Failure
    • Heart Health
    • Heart Rhythm
    • Hypertension
    • Interventional Cardiology
    • Mitral Valve
    • Pharmaceutics
    • Structural Heart Disease
    • TAVR
    • Tricuspid Valve
    • Vascular & Endovascular
  • Management
      |Management
    • Chest Pain Guidelines
    • Compensation
    • Economics
    • Education & Training
    • Legal News
    • Patient Care
    • Policy & Regulations
    • Professional Associations
    • Quality
    • Revenue
    • Staffing
  • Technology
      |Technology
    • AI
    • Cardiac Imaging
    • Cath Lab
    • CT
    • CVIS
    • ECG
    • Echo
    • EP Lab
    • Informatics
    • MRI
    • Nuclear Cardiology
    • Remote Monitoring
  • Videos
  • Conferences
      |Conferences
    • ACC
    • AHA
    • ASE
    • ASNC
    • ESC
    • EuroPCR
    • HFSA
    • HRS
    • SCAI
    • SCCT
    • SIIM
    • SNMMI
    • STS
    • TCT
    • VIVA
  • Custom Content
      |Custom Content
    • Experience Stories
    • Webinars & Videos
  • Subscribe
  • Forty Under 40 Award
      |Forty Under 40 Award
    • Class of 2026
    • Class of 2025

Search form

Home

News Alert: FDA approves another renal denervation system for hypertension

News You Need to Know Today
News Alert: FDA approves another renal denervation system for hypertension
Monday, November 20, 2023
Link to Twitter Link to Facebook Link to Linkedin Link to Vimeo

News Alert

FDA approves another renal denervation system for hypertension

This is the second time in a matter of weeks the FDA has approved an RDN system for uncontrolled hypertension. The SCAI issued a statement about this trend, calling it a “game-changer for both interventional cardiology and the treatment of hypertension."

READ MORE >
Medtronic Symplicity Spyral renal denervation
Share on Twitter Share on Facebook Share on Linkedin

FDA approves another renal denervation system for hypertension

Share on Twitter Share on Facebook Share on Linkedin
Medtronic Symplicity Spyral renal denervation
This is the second time in a matter of weeks the FDA has approved an RDN system for uncontrolled hypertension. The SCAI issued a statement about this trend, calling it a “game-changer for both interventional cardiology and the treatment of hypertension."
READ MORE >

Innovate Healthcare thanks our partners for supporting our newsletters.
Sponsorship has no influence on editorial content.

Interested in reaching our audiences, contact our team

*|LIST:ADDRESSLINE|*

You received this email because you signed up for newsletters from Innovate Healthcare.
Change your preferences or unsubscribe here

Contact Us  |  Unsubscribe from all  |  Privacy Policy

© Innovate Healthcare, a TriMed Media brand
Innovate Healthcare

Recent Newsletters

Caring for COVID-19 patients leads to depression, distress for healthcare workers | More cardiology conferences canceled
Coronary Intervention & Surgery | March 2020
Cardiac injury in COVID-19 patients | Outcomes for homeless patients after heart attacks
The biggest COVID-19 news in cardiology, all in one place
Key data from the 2020 Cardiovascular Leadership Survey | COVID-19 updates | Low-dose aspirin recommendations
Emergency cardiovascular care & COVID-19 | Statins reduce risk of developing HF from breast cancer therapies
Healthcare Economics & Policy | March 2020

Pagination

    • First page « First
    • Previous page ‹‹
    • Page …346
    • Page 347
    • Page 348
    • Page 349
    • Page 350
    • Current page 351
    • Page 352
    • Page 353
    • Page 354
    • Next page ››
    • Last page Last »
  • Home
  • News
  • Article Archive
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Cardiovascular Business
  • HealthExec
  • Radiology Business
 
© 2026 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
 
Design by Adaptive Theme
Trimed Popup